TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer
NCT04471480
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
90
Enrollment
OTHER
Sponsor class
Conditions
ESCC
Interventions
DRUG:
TC/PD-1 inhibitor/anlotinib
Sponsor
Dong Wang